Indegene Ltd Q4 FY2026 Concall Summary

Key Takeaways

• First ₹1,000 crore quarter, full-year ₹3,500 crore: Both milestones were reached in FY26, driven by compounding across the customer portfolio, domain capabilities and technology stack.
• GenAI is converting from pilots to hard dollars: Six GenAI-led wins closed in Q4, spanning omnichannel orchestration, end-to-end commercialization, AI-driven pharmacovigilance and an agency-of-record pilot that compressed upstream brand work from 3 months to 3 days.
• Tectonic platform now has 5 customers and revenue visibility: Two customers transitioned from pilot to long-term engagements, and the largest customer signed a significant Tectonic deal in Germany at year-end, with additional markets in active conversation.
• Margins to improve in H2 FY27 as investments absorb: Management is on track to improve EBITDA margins in FY27, with the second half reverting to earlier higher levels as acquisition integration costs fade and growth delivers operating leverage.
• What to watch next quarter: Whether the largest customer converts its Tectonic engagement into visible growth toward a first $50 million-plus relationship, and whether the agency-led AOR pilot converts into a real engagement this financial year.

Revenue Model & Structural Differentiation

• Revenue partner, not cost partner: Indegene is embedded in the commercial and medical functions that generate revenue for life sciences customers, who come to grow revenue, accelerate launches and manage compliance, not to cut costs. AI acts as a growth enabler rather than a signal to reduce spend.
• Outcome-alliance commercial model already in place: The company operates on managed-outcome pricing that retains productivity benefits without dependence on timesheet or input prices, a model that aligns naturally with AI-driven efficiency gains.
• Revenue per employee reached ~USD 75,000: Up from USD 56,000 three years ago and USD 66,000 last year, driven by embedding technology and AI into delivery. The Transform AI program targets a further step change as the company wins upstream in adjacent areas and new AI-driven revenue pools.
• Only player combining deep domain, embedded AI platforms and outcome ownership at enterprise scale: True competition is agencies and CROs, and GenAI is accelerating share gains from them as spend consolidates into specialized technology-led partners.

Manish Gupta: "Indegene is not an IT services company that happens to serve life sciences. Indegene is the strategic operating partner for the life science industry, purpose built over 27 years to design and run complex regulated commercial, medical and R&D operating models that define how this very important industry works."

Customer Portfolio & Growth Dynamics

• Top 20 revenue grew from ₹2,208 crore to ₹2,520 crore in FY26: Growth was driven by portfolio breadth and recurring engagements, even though the largest customer was broadly stable with a hold due to a delayed breakthrough that arrived at year-end.
• Third customer crossed the $25 million revenue threshold: The largest customer is expected to become the first $50 million-plus customer in FY27 as the Tectonic engagement in Germany converts to visible growth.
• Beyond the top 20, growth is accelerating: Total active customers grew from 73 to 91, and customers above $1 million annual revenue grew from 41 to 53, a roughly 30% increase. Growth in this cohort outpaced the top 20 on a percentage basis, demonstrating the land-and-expand model working further down the pyramid.
• $10 million-plus client count stable at 10: One client sits just below the threshold. Customers are taking more time to change operating models and adopt platforms, but management is bullish the cohort will increase as cycle times and internal change management progress.
• Biotech and small-company expansion accelerating: The segment is getting tailwinds from an improving U.S. funding environment, and Indegene is rapidly expanding its mid-sized and small company relationships.

Manish Gupta: "We are a revenue partner, not a cost partner. We are embedded in the commercial and medical functions that generate revenue for our customers. ... These customers don't come to us to cut costs, they come to grow their revenue, accelerate launches, improve pipeline success, manage compliance and risk for them."

GenAI & Next-Generation Operating Models

• Six GenAI-led wins in Q4 demonstrate breadth: They span omnichannel orchestration with a top-5 customer using the Invisage platform, end-to-end commercialization for a midsized biotech, a complete product launch for an emerging pharma company, AI-driven pharmacovigilance for a large medical devices client, a global innovation center reimagining R&D operations with GenAI to accelerate FDA submissions, and an agency-led AOR pilot.
• Five next-generation operating models are being defined: One-Click submissions, Human-less Medical Legal Review, Agentic AOR, AI-embedded engagement, and Intelligent R&D operations. Each replaces a manual, fragmented industry process with a platform-driven, AI-embedded one that Indegene believes it will define as a category in the years to come.
• Agency-led AOR pilot compressed upstream brand work from 3 months to 3 days: Demonstrated with a top-20 company, the model runs without a traditional agency. Management is confident the pilot will convert into a real engagement in FY27.
• Global innovation center model could be structural: Set up for a company with over $100 billion market cap, it reimagines R&D operations with GenAI. If it scales as anticipated, it represents a structural change in how pharma companies approach R&D operations.
• Domain knowledge is the moat, not the AI tools: GenAI equalizes access to technology but not to knowledge. Every service firm has the same foundation models and APIs; what separates winners is the depth of domain knowledge and how systematically it is converted into agentic, human-in-the-loop workflows that deliver real business outcomes.

Manish Gupta: "3 months to 3 days. This is what we demonstrated in a top 20 company for a very strategic upstream brand work. We piloted an Agency-of-record model without the agency."

Tectonic Platform

• Five customers secured, two transitioned from pilot to long-term engagements: The Q4 win in Germany with the largest customer was a significant breakthrough that had been highly anticipated and delayed through FY26.
• On track to become a material growth driver for enterprise commercial in FY27: The largest customer is expected to convert the Tectonic engagement into visible growth, and conversations for additional markets are active.
• A multi-year omnichannel deal exceeding $10 million in ACV closed in Q3 FY26: Revenue conversion from this deal begins in the latter half of FY27.

Margins, Cash Flow & One-Time Items

• EBITDA margin improvement expected in FY27: Management is on track to improve profitability, with the second half of FY27 reverting to earlier higher-margin levels as investments get fully absorbed and deliver growth.
• PAT to see significant upward movement in FY27: Positive impact from interest income on high cash balances with stable yields, amortization stabilizing and coming off in the latter half of FY27, and the fading impact of one-off and exceptional items.
• Operating cash flow was ₹650.8 crore, a 162% ratio on PAT: Driven by higher non-cash expenses and amortization, plus DSO improvement to 63 days from 72 days. Free cash flow was ₹606.5 crore, and the cash position remained strong despite ₹725.3 crore in acquisition outflows.
• ₹20.3 crore provision made for TCPA lawsuit settlement: The U.S. class action from 2020 alleges breach of the Telephone Consumer Protection Act and relates to a FY19-20 engagement using fax as an outreach channel, which is no longer active. Mediation is close to completion with terms being drafted and court approval awaited. Management believes no further such liability exposures exist.
• BioPharm integration completed ahead of schedule: Transition services from the seller were originally planned to conclude end of March but wrapped toward end of February. G&A synergies are anticipated in the next quarter itself, along with synergies on data subscriptions, business operations and go-to-market.
• Margin range philosophy: Maintaining a broad margin range is very doable; anything above that range will be reinvested in the business.

AI Moat & Competitive Positioning

• In the AI era, the competitive structure is being rewritten in Indegene's favor: Agency, rep-office and CRO spend is consolidating into specialized technology-led partners, and Indegene is positioned as the most credible such partner in life sciences.
• Medium-term defensibility rests on domain expertise that LLMs cannot yet replicate: LLMs still lack the reliability needed for operating-grade work, and the human in the loop is becoming even more important. An FDA warning letter to a company whose output looked AI-generated was cited as evidence.
• Long-term defensibility remains an open question: Management gave a detailed medium-term defense covering 3-5 years but stated that beyond that, "the jury is still out" on whether LLMs could commoditize domain knowledge.
• Generics market is not the priority: Some revenues come from generics, but the company is prioritizing innovative pharma companies where it believes it will have $100 million clients. Whether generics represent a scalable market at Indegene's revenue-per-employee level was not directly addressed.

Manish Gupta: "LLMs still don't have the reliability when you're talking about in operating grade. So, the human in loop is going to be even more important. There has been an FDA call out to one of the companies in just last 2 weeks a warning letter that looks AI generated."

Guidance & Commitments

Key Metrics